Raymond James Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $72

Benzinga Newsdesk www.benzinga.com Positive 79.8%

Neg 0% Neu 0% Pos 79.8%

Raymond James analyst Tiago Fauth initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Outperform rating and announces Price Target of $72.